| Literature DB >> 28820497 |
Abstract
The majority of currently used anesthetic agents are derived from or associated with natural products, especially plants, as evidenced by cocaine that was isolated from coca (Erythroxylum coca, Erythroxylaceae) and became a prototype of modern local anesthetics and by thymol and eugenol contained in thyme (Thymus vulgaris, Lamiaceae) and clove (Syzygium aromaticum, Myrtaceae), respectively, both of which are structurally and mechanistically similar to intravenous phenolic anesthetics. This paper reviews different classes of phytochemicals with the anesthetic activity and their characteristic molecular structures that could be lead compounds for anesthetics and anesthesia-related drugs. Phytochemicals in research papers published between 1996 and 2016 were retrieved from the point of view of well-known modes of anesthetic action, that is, the mechanistic interactions with Na⁺ channels, γ-aminobutyric acid type A receptors, N-methyl-d-aspartate receptors and lipid membranes. The searched phytochemicals include terpenoids, alkaloids and flavonoids because they have been frequently reported to possess local anesthetic, general anesthetic, antinociceptive, analgesic or sedative property. Clinical applicability of phytochemicals to local and general anesthesia is discussed by referring to animal in vivo experiments and human pre-clinical trials. This review will give structural suggestions for novel anesthetic agents of plant origin.Entities:
Keywords: general anesthetic; lead compound; local anesthetic; pharmacological mechanism; phytochemical; plant origin
Mesh:
Substances:
Year: 2017 PMID: 28820497 PMCID: PMC6152143 DOI: 10.3390/molecules22081369
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Local anesthetics derived from the plant alkaloid cocaine.
Figure 2General anesthetics associated with plant terpenoid thymol and eugenol.
Figure 3Terpenoids with local anesthetic activity.
Figure 4Alkaloids with local anesthetic activity.
Figure 5Polyphenolic flavonoids and stilbenoid with local anesthetic activity.
Figure 6Terpenoids with general anesthetic activity.
Figure 7Alkaloids with general anesthetic activity.
Figure 8Flavonoids with general anesthetic activity.
Phytochemicals with anesthetic activity.
| Phytochemicals | Activities | Experiments | Results | References |
|---|---|---|---|---|
| Terpenoids | ||||
| Linalool | LA | In vitro: Monitoring of compound action potentials in frog sciatic nerves | Exerted local anesthetic effects at 7.5–30 mM as well as 3.5–30 mM lidocaine | [ |
| Linalool
| LA | In vivo: Administration in rabbit conjunctival sac | Depressed conjunctival reflexes by 0.03–2.5 mg/mL administration | [ |
| Linalool | LA | In vitro: Patch-clamp recording of rat sciatic nerves and rat dorsal root ganglion neurons | Reversely blocked nerve excitability and inhibited voltage-gated Na+ currents at sub-micromolar concentrations | [ |
| (−)-Menthol
| LA | In vitro and in vivo: Evaluation of the activity using rat phrenic nerve hemidiaphragm and by rabbit conjunctival reflex test | Reduced the electrically evoked contractions at 0.1–100 ng/mL and increased the number of stimuli to provoke the conjunctival reflex at 30–300 μg/mL | [ |
| Menthol | LA | In vitro: Patch-clamp recording of rat dorsal root ganglion neurons | Inhibited tetrodotoxin-resistant Nav1.8 and Nav1.9 and tetrodotoxin-sensitive Na+ channels depending on micromolar concentration, voltage and frequency | [ |
| Carvacrol
| LA | In vitro: Recording of compound action potentials in frog sciatic nerves | Reduced compound action potential peak amplitudes (IC50 = 0.34–7.2 mM) and inhibited nerve conduction by blocking tetrodotoxin-sensitive voltage-gated Na+ channels | [ |
| Carvacrol | LA | In vitro: Monitoring of rat sciatic nerve compound action potentials and patch-clamp recording of rat dorsal root ganglion neurons | Reversely blocked the excitability of sciatic nerves (IC50 = 0.5 mM) and reduced voltage-gated Na+ currents (IC50 = 0.37 mM) | [ |
| Carvacrol | AA | In vivo: 50–100 mg/kg (p.o.) administration to mice, followed by acetic acid-induced abdominal constriction, formalin injection and hot plate tests | Inhibited nociception induced by different methods | [ |
| (−)-Carvone | AA | In vivo: 100–200 mg/kg (i.p.) administration to mice | Inhibited acetic acid-induced writhing and formalin-induced hind paw nociception | [ |
| Estragole | LA | In vitro: Patch-clamp recording of rat dorsal root ganglion neurons | Inhibited total Na+ currents (IC50 = 3.2 mM) and tetrodotoxin-resistant Na+ currents (IC50 = 3.6 mM) | [ |
| Citral | LA | In vitro: Monitoring of compound action potentials in rat sciatic nerves | Inhibited compound action potentials (IC50 = 0.23 mM) | [ |
| α-Terpineol
| LA | In vitro and in vivo: Evaluation of the activity using rat phrenic nerve-hemidiaphragm and by rabbit conjunctival reflex test | Reduced the electrically evoked contractions at 0.01–1 μg/mL and increased the number of stimuli to evoke the conjunctival reflex at 10–100 μg/mL | [ |
| AA | In vivo: 50–200 mg/kg (i.p.) administration to mice, followed by acetic acid-induced writhing and formalin-induced hind paw licking tests | Showed significant antinociceptive effects in both tests | [ | |
| β-Caryophyllene | LA | In vitro and in vivo: Evaluation of the activity using rat phrenic nerve-hemidiaphragm and by rabbit conjunctival reflex test | Reduced the electrically evoked contractions at 0.1 ng/mL to 1.0 μg/mL and increased the number of stimuli to evoke the conjunctival reflex at 10 μg/mL to 1.0 mg/mL | [ |
| Alkaloids | ||||
| Lappaconitine other neurotoxins | LA | In vivo: Rabbit corneal reflex test to drop test solutions (0.01–1%) into the conjunctival sac and cat neck trunk anesthesia to inject test solutions (0.1 mL of 0.1–0.5%, i.c. and s.c.) | Showed greater potency and longer duration of anesthesia than lidocaine and procaine | [ |
| Aconitine 3-Acetylaconitine | AA | In vivo: Intravenous administration to mice, followed by formaldehyde injection (s.c.) to induce hyperalgesia | Showed antinociceptive effects in the early phase (ED50 = 0.027–0.028 mg/kg) and the late phase (ED50 = 0.077–0.097 mg/kg) | [ |
| Bulleyaconitine A | LA | In vivo: Injection of 0.2 mL test solution into rat sciatic notch | Blocked sensory and motor functions of the sciatic nerves at 0.375 mM | [ |
| Bulleyaconitine A | LA | In vitro and in vivo: Recording of Na+ currents of human embryonic kidney cells expressing Nav isoforms and measurement of the cutaneous trunci muscle reflex after injection (s.c.) of 0.6 mL test solution | Blocked Nav1.7 and Nav1.8 Na+ currents at 10 μM and induced the complete nociceptive blockade lasting for ~3 h at 0.125 mM | [ |
| 3-Acetylaconitine | AA | In vivo: 50–125 μM (s.c.) co-injection with 0.5% lidocaine and epinephrine (1:200,000) to rats | Produced the complete analgesia lasting for 3–12 h | [ |
| Lappaconitine | AA | Pre-clinical: Patients received epidural injections of 0–12 mg lappaconitine | Produced satisfactory analgesia depending on dosages | [ |
| Lappaconitine | AA | Pre-clinical: Patients received epidural injections of test solutions consisting of 12 mg lappaconitine, 12 mg lappaconitine plus 22.5 mg bupivacaine or 22.5 mg bupivacaine | Epidural co-injection of lappaconitine with bupivacaine induced analgesia with greater potency, earlier initiation and longer maintenance than lappaconitine alone and bupivacaine alone | [ |
| Flavonoids | ||||
| (−)-Epigallo-catechin-3-gallate | LA | In vitro: Measurement of Na+ currents in rat dorsal root ganglion neurons | Inhibited tetrodotoxin-sensitive and tetrodotoxin-resistant Na+ currents | [ |
| Genistein Daidzein | LA | In vitro: Measurement of Na+ currents in cultured rat brain neurons | Blocked voltage-sensitive Na+ channels (IC50 = 60 μM for genistein and 195 μM for daidzein) | [ |
| Stilbenoid | ||||
| Resveratrol | LA | In vitro: Measurement of Na+ currents in rat dorsal root ganglion neurons | Suppressed tetrodotoxin-sensitive and tetrodotoxin-resistant Na+ channels | [ |
| Terpenoids | ||||
| Aristolen-1(10)-en-9-ol | S | In vivo: Spontaneous vapor administration to mice | Inhibited the locomotion of caffeine-treated mice at 300 μg/cage and prolonged the time of pentobarbital-induced sleep | [ |
| Isopulegol
| GA-like | In vitro: Determination of the effects on GABAA receptor α1β2 or α1β2γ2 subunits expressed in | Modulated GABAA receptor functions at 3–300 μM independently of the γ2 subunit | [ |
| Valerenic acid | GA-like | In vitro: Determination of the effect on GABAA receptors in neonatal rat brainstem preparations | Inhibited muscimol-sensitive neurons (IC50 = 23 μM) | [ |
| Valerenic acid | GA-like | In vitro and in vivo: Radioligand binding assay with crude rat brain membranes and 1–6 mg/kg (i.p.) and 10 mg/kg (p.o.) administration to mice | Interacted allosterically with benzodiazepine and GABA binding site of GABAA receptors | [ |
| Linalool | S | In vivo: Placed mice in a chamber of an atomosphere saturated 1% or 3% vapor | Produced sedation and increased the time of pentobarbital-induced sleep | [ |
| Menthol | GA-like | In vitro: Determination of the effect on recombinant human GABAA receptors expressed in | Enhanced sub-maximal GABA currents at 3–300 μM | [ |
| Menthol | GA-like | In vitro: Whole-cell voltage clamp recording of rat midbrain periaqueductal grey neurons | Prolonged at 150–750 μM the duration of spontaneous inhibitory postsynaptic potentials mediated by GABAA receptors | [ |
| Thymol
| GA-like | In vitro: Determination of the effects on primary cultures of mouse cortical neurons at micromolar concentrations | Enhanced [3H]flunitrazepam binding to GABAA receptors and increased 2 μM GABA-evoked Cl− influx | [ |
| Thymol | GA-like | In vitro: Determination of the effects on human GABAA receptor subunit combinations expressed in | Potentiated EC20 GABA response at 1–100 μM | [ |
| Thymol | GA-like | In vitro: Determination of the positive allosteric modulatory effects on GABAA receptors in primary cultures of mouse cortical neurons | Enhanced 5 μM GABA-induced Cl− influx (EC50 = 12 μM) and directly enhanced Cl− influx (EC50 = 135 μM) | [ |
| Alkaloids | ||||
| Harman | A | In vivo: 2.5–10 mg/kg (i.p.) administration to rats | Decreased the time of immobility in a forced swim test and increased the time spent in open arms in an elevated plus maze | [ |
| Harman
| S | In vivo: 2.5–15 mg/kg (i.p.) administration to mice | Decreased the time of immobility | [ |
| Flavonoids | ||||
| (−)-Epigallo-catechin-3-gallate | H | In vivo: 5–20 mg/kg (p.o.) administration to mice | Prolonged the time of pentobarbital-induced sleep | [ |
| Apigenin | S | In vivo: 0.6 mg/kg (p.o.) administration to mice | Induced sedation | [ |
| Chrysin | A | In vivo: 2 mg/kg (i.p.) administration to rats | Induced anxiolysis | [ |
| Baicalein Baicalin | A | In vivo: 10–20 mg/kg (i.p.) administration to mice | Induced anxiolysis | [ |
| Kaempferol | A | In vivo: 0.02–1.0 mg/kg (p.o.) administration to mice | Induced anxiolysis | [ |
| Wogonin | GA-like | In vitro and in vivo: Radioreceptor binding assay with rat forebrain synaptosomal membranes, electrophysiological experiment with rat dorsal root ganglion neurons and 7.5–30 mg/kg (p.o.) administration to mice | Showed the affinity for the benzodiazepine site of GABAA receptors ( | [ |
| Isoliquiritigenin | GA-like | In vitro and in vivo: Radioreceptor binding assay with rat cerebral cortex membranes, electrical measurement of rat dorsal raphe neurons and 25–50 mg/kg (p.o.) administration to mice | Showed the affinity for GABAA-benzodiazepine receptors ( | [ |
| Isoliquiritigenin | GA-like | In vitro: Measurement of the GABAergic synaptic renponses by the whole-cell patch clamp technique | Prolonged at 1 μM the decay of spontaneous inhibitory postsynaptic currents mediated by GABAA receptors | [ |
| Glabrol | H | In vivo: 25–50 mg/kg (p.o.) administration to mice | Increased the sleep duration and decreased the sleep latency in mice treated with pentobarbital | [ |
| Apigenin | A | Pre-clinical: Randomized, double-blind, placebo-controlled trial for outpatients with 220 mg chamomile extracts standardized to a content of 1.2% apigenin | Showed clinically meaningful difference from controls in anxiety rating scores | [ |
| Wogonin
| A | Pre-clinical: Double-blind and placebo-controlled study for human subjects with 100–200 mg skullcap extracts containing flavones | Exhibited anxiolytic effects | [ |
LA: local anesthetic; GA: general anesthetic; AA: antinociceptive/analgesic; S: sedative; A: anxiolytic; H: hypnotic.